Zura Bio Ltd

Zura Bio Ltd (Nasdaq: ZURA) is a clinical-stage biopharmaceutical company focused on immunology and inflammatory disease, which completed its de-SPAC business combination and began trading publicly in 2023. The company filed an 8-K current report with the SEC on June 2, 2023, under accession number 0001104659-23-067181, disclosing a material corporate event following its transition to a publicly listed entity. Zura Bio operates in the healthcare and life sciences sector, developing targeted therapies for immune-mediated conditions. The filing reflects the ongoing post-merger reporting obligations standard for newly public companies that have completed a SPAC transaction. Sign up at SpacDesk for full filing data, deal timelines, and sponsor profiles on Zura Bio and hundreds of other SPAC transactions.